
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
In-depth coverage of the 2017 American Academy of Pediatrics Annual Meeting in Chicago, Illinois.
Link to tag page below...






